Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system

A method of treatment of one illness of a human female patient,

• the illness being selected from the group consisting of:
• cervical cancer,
• cervical intraepithelial neoplasia (CIN), and
• human papillomavirus (HPV) infection of the female genital system,
• by locally delivering, directly to cervix of a female genital system, at least one therapeutic agent selected from the group consisting of:
• a chemotherapeutic medication, and
• a targeted therapy medication,
• wherein locally delivering comprises implanting a medical device in correspondence of the cervix, the medical device having:
• a stem positioned into the cervix of a human female genital system and
• at least a drug carrying portion associated to at least a surface of the stem, the therapeutic agent being contained in the drug carrying portion which comes into direct contact with the cervix tissues.

A method of treatment of one illness of a human female patient,

• the illness being selected from the group consisting of:
• cervical cancer, and
• cervical intraepithelial neoplasia (CIN),
• by locally delivering, directly to the cervix of a female genital system, at least one therapeutic agent comprising Taxol,
• wherein locally delivering comprises implanting a medical device in correspondence of the cervix, the medical device having:
• a stem positioned into the cervix of a human female genital system and
• at least a drug carrying portion associated to at least a surface of the stem, the therapeutic agent being contained in the drug carrying portion which comes into direct contact with the cervix tissues,
• wherein Taxol is released at a dose of from 1 to 30 mg (milligrams) per week.

A method of treatment of one illness of a human female patient,

• the illness being selected from the group consisting of:
• cervical cancer,
• cervical intraepithelial neoplasia (CIN), and
• human papillomavirus (HPV) infection of the female genital system,
• by locally delivering, directly to the cervix of a female genital system, at least one therapeutic agent comprising Cisplatin,
• wherein locally delivering comprises implanting a medical device in correspondence of the cervix, the medical device having:
• a stem positioned into the cervix of a human female genital system and
• at least a drug carrying portion associated to at least a surface of the stem, the therapeutic agent being contained in the drug carrying portion which comes into direct contact with the cervix tissues,
• and wherein Cisplatin is released from 1 to 40 mg (milligrams) per week.